USODA
Financiado
Upscaling Synthesis of Ordered mesoporous silica material for Drug delivery Appl...
FORMAC Pharmaceuticals NV is actively developing and commercialising an innovative and proprietary drug delivery technology to increase the oral bioavailability of poorly aqueous soluble drugs. Those molecules represent up to sev...
FORMAC Pharmaceuticals NV is actively developing and commercialising an innovative and proprietary drug delivery technology to increase the oral bioavailability of poorly aqueous soluble drugs. Those molecules represent up to seventy percent of the compounds in discovery pipelines and up to forty percent of the currently marketed drugs. Based on the use of Ordered Mesoporous Silica (OMS) materials, FORMAC’s platform enables clients’ molecules to be formulated as oral drug products for early development, life cycle management or generic development. FORMAC is key leader in this emerging field with more than twenty different collaboration agreements and fifty molecules tested. Together with its validation in a human clinical setting, numerous regulatory consultations on EU level have been conducted. FORMAC is now ready to secure its first licensing deal with a pharmaceutical or generic company. However, some remaining challenges are hampering full deployment of FORMAC’s technology platform. Given its development stage, the company is still facing (i) an unfavourable cost of goods profile linked to the current OMS synthesis process and (ii) its limited manufacturing scale. The current proposal will unlock the first limitation and create possibilities for further upscaling. FORMAC’s ultimate goal is to bring OMS based drug delivery to the global market.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2015-05-01
Fecha Fin: 2015-11-30
Fecha Fin: 2015-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2015-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
FORMAC PHARMACEUTICALS NV
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.54M€ |
Participante